Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
US Scientists have developed a simple scoring system (DiaRem), based on four readily available preoperative patient characteristics, that can predict which candidates for gastric bypass surgery are likely to achieve diabetes remission within 5 years.
"Our novel DiaRem score will give patients and physicians a scientifically valid way of assessing the merits of gastric bypass surgery for treating diabetes and deciding whether additional measures should be taken to improve the odds of remission"*, explains lead author George Argyropoulos from the Geisinger Health System, Danville, PA, USA, in The Lancet Diabetes & Endocrinology.
Roux-en-Y gastric bypass (RYGB) is used to help people who are morbidly obese lose weight. As a side effect, it has been shown to resolve or improve type 2 diabetes in roughly 60% of patients. It may also be useful to treat diabetes in people who are not morbidly obese. But, currently there is no accurate method to determine which patients have the greatest likelihood of remission after surgery.
To create the scoring system, the researchers retrospectively analysed the outcomes of 690 obese patients with type 2 diabetes who underwent RYGB between 2004 and 2011 at the Geisinger Health System Clinic in Danville (PA, USA), of whom 463 (63%) achieved partial or complete remission**.
Multiple logistic regression models considered 259 clinical variables to identify independent predictors of early remission (beginning within the first 2 months after surgery and lasting a minimum of 12 months) and late remission (beginning more than 2 months after surgery and lasting at least another 12 months).
Patients were assigned a weighted DiaRem score (ranging from 0 to 22) based on four factors that were independently predictive of remission - insulin use, age, haemoglobin A1c concentration (HbA1c; a measure of blood sugar), and type of anti-diabetic drugs. DiaRem scores were derived by assigning a certain number of points to each of the four factors.
The researchers found that patients with a low DiaRem score had the highest chance of remission after surgery, while those with a higher score were less likely to achieve remission.
"For example, an individual with a BMI of 39 kg/m² [morbidly obese] and a DiaRem score of 22 could benefit from RYGB surgery in terms of weight loss, but would have low probability of diabetes remission", explains Argyropoulos.
The performance of the score was validated in two independent cohorts totalling 389 patients based on diabetes remission at 14 months. As in the primary cohort, the proportion of patients achieving remission was highest for the lowest scores and lowest for the highest scores.
According to Argyropoulos, "Our score is robust with various definitions of diabetes remission (complete, partial, or a combination) and also predicts the probable improvement in glycaemic control after RYGB surgery."
Writing in a linked Comment, Dimitri J. Pournaras and Carel W. le Roux from Imperial College London, UK say, "The DiaRem score could help with selection of appropriate treatment and management of expectations held by both the patient and the multidisciplinary team involved in the patient's care. Additionally, it could scientifically improve the comparison of different surgical procedures by allowing appropriate stratification of probability of remission. However, further prospective studies are needed to validate these potential uses. Future research in this area will increase the accuracy of outcome predictions in different populations, age groups, and interventional approaches. This research could even challenge present guidelines for provision of weight-loss surgery, which mostly depends on BMI [body mass index]."
*Quote direct from author and cannot be found in text of Article.
**Partial remission: haemoglobin Alc (HbA1c) concentration less 6.5%, fasting glucose concentrations less than 7.0 mmol/L, and no use anti-diabetic drugs for at least 12 months. Complete remission: Hba1c level less than 6.0%, fasting glucose concentrations less than 5.55 mmol/L, and no use of anti-diabetic drugs for at least 12 months.
The Lancet: September 13, 2013 http://dx.doi.org/10.1016/S2213-8587(13)70070-6
Christopher D Still, G Craig Wood, Peter Benotti, Anthony T Petrick, Jon Gabrielsen, William E Strodel, Anna Ibele, Jamie Seiler, Brian A Irving, Melisa P Celaya, Robin Blackstone, Glenn S Gerhard, George Argyropoulos
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Obesity / Weight Loss / Fitness category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Lancet, The. "New scoring system predicts likelihood of diabetes remission after weight-loss surgery." Medical News Today. MediLexicon, Intl., 13 Sep. 2013. Web.
12 Dec. 2013. <http://www.medicalnewstoday.com/releases/265991>
Lancet, T. (2013, September 13). "New scoring system predicts likelihood of diabetes remission after weight-loss surgery." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/265991.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.